Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Investors holding tight for the most part

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Nov 18, 2022 3:33pm

126 Views

Post# 35111441

RE:RE:Investors holding tight for the most part

Quentin30 wrote: How's that green finish looking Angler101..??

This stock will remain flat until their is pivotal data - that may come from AN... but as their safety run in was a copy of IN-213, we shouldn't expect anything better. It should be the same.

If it's worse, then this could explain the disinterest in IND-213 data, and ONCY having to re-run the trial as Bracelet-1. No matter, this company now has just 9 months to prove itself... fail, and they're dead in the water...

One more negative post Quiiiintiiiin!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario